Tesamorelin Purity: 4035 Lab Tests Across 1232 Identified Manufacturers
38 studies on Tesamorelin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 4,035 published third-party lab tests of Tesamorelin across 1,232 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.16%. Within this published corpus, 34 positive purity results were below 90%, and 227 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
Tesamorelin average prices
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $11.60 | $5.50–$14.50 | $2.32 | 5 sources · 5 offers |
| 10 mg | $21.28 | $18.50–$26.00 | $2.13 | 9 sources · 9 offers |
| 20 mg | $37.75 | $36.50–$39.00 | $1.89 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
We tested 4035 Tesamorelin batches across 1232 identified manufacturers
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 896 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Top 3 vendor evidence profiles for Tesamorelin
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 74 | 99.38% | 1 of 65 (1.5%) 1 0% / not detected · 0 wrong compound · 9 unclassified | Reveal with Pro → | |
| #2 | 51 | 99.4% | 0 of 42 (0.0%) 0 0% / not detected · 0 wrong compound · 9 unclassified | Reveal with Pro → | |
| #3 | 30 | 96.14% | 0 of 30 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #101333 (99.82%) · #100831 (99.93%) · #100832 (99.94%) · #100833 (99.34%) · #101095 (99.94%) · #101170 (99.21%)
Tesamorelin studies and clinical research
-
Canadian Society of Plastic Surgeons Announces 78th Annual Meeting in Toronto for June 2025
The Canadian Society of Plastic Surgeons will host its 78th Annual Meeting in Toronto, ON, from June 3-7, 2025, with Dr. Nick Carr as President.
-
Tesamorelin and GLP-1R Agonists Demonstrate Distinct Pathways for Visceral Fat Reduction in HIV
This case report underscores that personalized treatment strategies are crucial for managing EVAF in PLWH. For peptide users and clinicians, it reinforces that Tesamorelin and GLP-1R agonists are not interchangeable b…
-
GLP-1R Agonists Show Reproducible Evidence for Knee Osteoarthritis Symptom Relief, While Other Peptides Lack High-Quality Data
This review highlights a critical distinction for peptide users and clinicians: only GLP-1R agonists currently possess reproducible, high-quality evidence for a specific musculoskeletal indication (knee osteoarthritis…
-
Tesamorelin Explored for Improving Heart Health in HIV Patients with Fat Redistribution
-
Tesamorelin Long-Term Safety Study in HIV Patients Terminated Early
The premature termination of this 10-year observational study means that crucial long-term safety data for Tesamorelin in HIV-associated abdominal lipohypertrophy remains largely uncollected. This is significant becau…
-
Understanding Differences in HIV/HCV Patients Accessing Hepatitis C Treatment
These findings are crucial for developing targeted interventions to improve HCV treatment uptake and cure rates among vulnerable HIV/HCV co-infected populations. By understanding the specific barriers faced by untreat…
-
Tesamorelin Study for COPD Muscle Wasting Terminated Early Due to Low Enrollment
The early termination of this study represents a missed opportunity to explore a potential therapeutic avenue for COPD-related muscle wasting, a condition with significant unmet medical needs. Tesamorelin, a synthetic…
-
Tesamorelin Trial Investigates Enhanced Nerve Regeneration After Injury
Peripheral nerve injuries often result in debilitating long-term deficits, making effective therapeutic interventions critically important. If Tesamorelin proves successful in this trial, it could represent a novel ph…
-
Tesamorelin Explored for Cognitive Benefits in Aging HIV Patients
The successful outcome of this trial could represent a significant advancement in managing HIV-associated neurocognitive disorders (HAND), which are a growing concern in the aging HIV population. If tesamorelin proves…
-
GHRH Analog Reduces Liver Inflammation and Damage in Fatty Liver Disease
This study highlights the GHRH analog as a promising therapeutic candidate for NAFLD and NASH, offering a novel approach to combat liver inflammation and damage. By targeting immune activation and multiple detrimental…
-
Tesamorelin Effectively Reduces Visceral Fat in HIV Patients, Regardless of Dorsocervical Fat
This analysis provides strong evidence that tesamorelin can be broadly considered for treating excess visceral adipose tissue in people with HIV, irrespective of the presence of dorsocervical fat. This simplifies clin…
-
Tesamorelin Shows Promise for HIV Patients on Integrase Inhibitors
-
CROI 2024: New Insights into HIV's Neuropsychiatric Complications
These findings underscore the critical need for continued research into HIV's impact on the central nervous system, even in the era of effective ART, and highlight the multifaceted nature of neuropsychiatric complicat…
-
Medications Linked to Carpal Tunnel Syndrome in Major Pharmacovigilance Study
This study provides critical evidence linking specific medications to Carpal Tunnel Syndrome, highlighting a previously underrecognized risk. The findings could lead to updated prescribing guidelines and enhanced pati…
-
Tesamorelin Improves Brain Function in HIV Patients with Abdominal Obesity
These findings are highly significant, as they suggest that Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, could offer a novel therapeutic strategy for a debilitating comorbidity in PLWH. The dual bene…
-
Understanding Liver Disease in People Living with HIV
This comprehensive review is crucial for raising awareness among clinicians about the high burden of MASLD in PLWH and its potential for severe liver outcomes. By consolidating current knowledge, it provides a valuabl…
-
Tesamorelin Improves Body Composition and Liver Fat in HIV Lipodystrophy
This meta-analysis provides robust evidence supporting Tesamorelin as a highly effective and safe therapeutic option for managing HIV-associated lipodystrophy. The comprehensive improvements in body composition, parti…
-
Novel Peptide Preserves Muscle Mass During Weight Loss in Obese Adults
The preservation of lean body mass during weight loss is a critical factor for long-term health, metabolic function, and sustained weight management. This study's findings demonstrate that MyoPreserve offers a novel p…
-
Antiretroviral Therapy Plus High-Calorie Diets Harms Rodent Hearts
This research highlights a critical interaction between cART and dietary patterns, suggesting that certain high-calorie diets may exacerbate the cardiotoxic effects of antiretroviral drugs. The findings underscore the…
-
Tesamorelin's Impact on Diabetic Retinopathy in HIV Patients with Lipohypertrophy
The termination of this Phase 4 clinical trial means a critical knowledge gap remains regarding the long-term ocular safety of tesamorelin in HIV-infected patients with diabetes. Understanding the potential risks or b…
-
Tesamorelin: Targeting Visceral Fat in HIV-Associated Lipodystrophy
The ability of Tesamorelin to specifically reduce visceral fat represents a significant advancement in managing HIV-associated lipodystrophy, a condition that severely impacts quality of life and metabolic health. Thi…
-
GHRH Therapy Explored for Improving Heart Function in Congestive Heart Failure
These findings suggest that GHRH therapy could represent a novel therapeutic strategy for improving cardiac function and quality of life in older adults with congestive heart failure and reduced growth hormone effect.…
-
Tesamorelin Significantly Reduces Liver Fat in Adults with MASLD
This study provides compelling evidence that tesamorelin could be a highly effective pharmacological intervention for MASLD, addressing a critical unmet medical need. The significant reduction in liver fat observed su…
-
Tesamorelin's Impact on Body Fat in HIV Lipodystrophy Patients
-
Investigating Tesamorelin's Potential to Improve Sleep Apnea in Lipodystrophy
The intent behind this withdrawn study highlights a critical unmet need: finding effective treatments for sleep-disordered breathing in patients with lipodystrophy. If Tesamorelin could demonstrably improve sleep apne…
-
Tesamorelin Shows Promise for Reducing Liver Fat in Obese NAFLD Patients
These findings, if confirmed upon publication, would establish tesamorelin as a promising therapeutic option for NAFLD in obese individuals, addressing a critical unmet medical need. Given the high prevalence of NAFLD…
-
Tesamorelin's Drug Profile and Safety Explored in HIV Patients
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of…
-
Tesamorelin Plus Exercise to Boost Physical Function in HIV Patients
The potential for Tesamorelin to augment exercise benefits in HIV-positive individuals is highly significant. If successful, this intervention could offer a novel and more effective strategy to combat frailty and phys…
-
Tesamorelin's Short-Term Effects on Growth Hormone and Insulin in Healthy Men
Understanding Tesamorelin's short-term effects in healthy individuals is crucial for broadening its potential therapeutic applications beyond HIV-associated lipodystrophy. If Tesamorelin can safely enhance GH secretio…
-
Tesamorelin Investigated for Liver Fat and Histology in HIV Patients
-
GHRH Analogue Explored for Abdominal Fat and Heart Inflammation
This study, had it been completed, could have provided crucial evidence for a novel therapeutic strategy to mitigate cardiovascular risk in individuals with abdominal obesity. By demonstrating a direct link between GH…
-
Withdrawn Study Explored GHRH Analog for TBI-Related Insomnia in Service Members
The withdrawal of this study highlights a persistent gap in research for effective treatments for TBI-related insomnia, a condition that significantly impacts the quality of life for service members and veterans. Had …
-
Tesamorelin Reduces Visceral Fat and Improves Heart Health in HIV Lipodystrophy
This research highlights tesamorelin's potential as a targeted therapeutic option for managing HIV lipodystrophy, offering more than just cosmetic benefits. The significant reduction in visceral fat, coupled with impr…
-
New Method Improves Detection of Prohibited Growth Hormone Releasing Hormone Analogs
This study represents a significant advancement in the fight against doping in sports, specifically targeting growth hormone releasing hormone synthetic analogs. By identifying and characterizing previously unknown me…
-
Novel Nano LC-MS Method Boosts Detection of Growth Hormone Peptides in Urine
This highly sensitive and robust nano LC-Q/Orbitrap MS method represents a significant advancement in the detection of GHRH and its analogs, which are frequently abused performance-enhancing drugs. The enhanced sensit…
-
Tesamorelin Confirmed Effective for Long-Term HIV-Associated Lipodystrophy Treatment
This study is significant because it confirms the sustained efficacy and long-term safety of TH9507 (Tesamorelin) as a targeted treatment for HIV-associated lipodystrophy, a challenging side effect of ART. Reducing vi…
Research tools
Free, no account — handy when you're working with Tesamorelin.
